Gouda Ahmed M, Soltan Mohamed A, Abd-Elghany Khalid, Sileem Ashraf E, Elnahas Hanan M, Ateya Marwa Abdel-Monem, Elbatreek Mahmoud H, Darwish Khaled M, Bogari Hanin A, Lashkar Manar O, Aldurdunji Mohammed M, Elhady Sameh S, Ahmad Tarek A, Said Ahmed Mohamed
Department of Pharmacy Practice, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Department of Microbiology and Immunology, Faculty of Pharmacy, Sinai University-Kantara Branch, Ismailia, Egypt.
Front Mol Biosci. 2023 Feb 14;10:1123411. doi: 10.3389/fmolb.2023.1123411. eCollection 2023.
() and () are the most common Gram-negative bacteria associated with pneumonia and coinfecting the same patient. Despite their high virulence, there is no effective vaccine against them. In the current study, the screening of several proteins from both pathogens highlighted FepA and OmpK35 for in addition to HasR and OprF from as promising candidates for epitope mapping. Those four proteins were linked to form a multitope vaccine, that was formulated with a suitable adjuvant, and PADRE peptides to finalize the multitope vaccine construct. The final vaccine's physicochemical features, antigenicity, toxicity, allergenicity, and solubility were evaluated for use in humans. The output of the computational analysis revealed that the designed multitope construct has passed these assessments with satisfactory scores where, as the last stage, we performed a molecular docking study between the potential vaccine construct and associated immune receptors, TLR4 and TLR2, showing affinitive to both targets with preferentiality for the TLR4 receptor protein. Validation of the docking studies has proceeded through molecular dynamics simulation, which estimated a strong binding and supported the nomination of the designed vaccine as a putative solution for and coinfection. Here, we describe the approach for the design and assessment of our potential vaccine.
()和()是与肺炎相关且可共同感染同一患者的最常见革兰氏阴性菌。尽管它们毒力很强,但尚无针对它们的有效疫苗。在当前研究中,对这两种病原体的几种蛋白质进行筛选后,除了来自()的HasR和OprF外,还突出了FepA和OmpK35作为表位作图的有前景候选物。这四种蛋白质被连接起来形成一种多表位疫苗,该疫苗与合适的佐剂和PADRE肽一起配制,以完成多表位疫苗构建体。对最终疫苗的物理化学特性、抗原性、毒性、致敏性和溶解性进行了评估,以供人类使用。计算分析的结果表明,设计的多表位构建体已以令人满意的分数通过了这些评估,在最后阶段,我们对潜在疫苗构建体与相关免疫受体TLR4和TLR2进行了分子对接研究,结果显示该构建体对两个靶点都有亲和力,且对TLR4受体蛋白有优先亲和力。对接研究的验证通过分子动力学模拟进行,该模拟估计有很强的结合力,并支持将设计的疫苗提名为针对()和()共同感染的假定解决方案。在此,我们描述了设计和评估我们潜在疫苗的方法。